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Abstract 
Human immunodeficiency virus (HIV) infection leads to rise in HIV-RNA resulting in CD4 T-cell decline 
leading to AIDS-related illness. Knowing the effect of Antiretroviral Therapy (ART) on CD4 cell count is vital in 
assessing the progression of the disease and treatment planning for treatment.  This study sought to apply paired 
t-test distribution to assess the effect of CD4 cell count just before and after initiation of ART among HIV 
infected individuals. The target populations were HIV sero-converters enrolled in a prospective randomized 
placebo controlled trial in Nyanza region, Kenya.  CD4 cell count was measured at the time of sero-conversion 
and subsequently after very six months of follow up. Participants were referred for initiation of ART at patient 
support centre once the criteria for initiation was met and report back the ART regime they were put on and the 
date they were started on .  We applied paired t-test to assess the change in CD4 cell count after initiating ART. 
Use of ART within a median time of 9 months resulted rise in CD4 cell count by 241 cells per ul, 95% CI 
(60-422) which confirms the effect of ART in protecting depletion of CD4 cell count.  
Keywords: Sero-converters, Progression, ART, HIV, CD4 cells, t-test. 
 
1. Introduction  
Globally, the number of new HIV infections is estimated to range between 1.9 million to 2.7 million as at 2012 
(UNAIDS, 2013). Approximately 1,192,000 persons are currently living with HIV infection in Kenya with 
highest prevalence of about 15% in Kisumu County (KAIS, 2012) which is at least three folds higher than other 
regions of the country. Studies have shown 70-80% of the HIV infected experience intermediate disease 
progression resulting in development of AIDS-related illnesses within 6-10 years of acquiring HIV (Pantaleo and 
Fauci, 1996). A number of vitro studies and clinical trials (St Clair et al., 1995; Pagano and Chong,1995; 
Markowitz et al., 1995; Stein et al., 1996; Hammer et al., 1997; Collier et al.,1996; Cameron et al., 1997) and 
findings of observational studies (Egger et al., 1997;Chiasson et al., 1997; Hogg et al., 1998; Detels et al., 1998) 
have demonstrated the effectiveness of treating HIV-infected individuals with combinations of Anti-retroviral 
Therapy (ART). This has been estimated by a decrease in viral load to levels below the detection limits. The 
scale-up of ART represents an unprecedented effort to provide access to life-saving drugs to HIV-infected 
patients in resource-limited settings.  
The average rate of decline of CD4 cells ("CD4 slope") according to Mellors et al,(1997); Vlahov et al. (1998)  
is about 50/mm³ per year and the average viral burden (without therapy) is 30,000 to 50,000 copies/mL.  Few 
records of sero-converter cohorts exist in low-income and middle-income countries, and the number of 
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participants enrolled is relatively small and so has resulted in collaborative analyses of individual participant data 
from several studies (Stewart and Tierney, 2002). Also a limited number of studies have estimated CD4 cell loss 
in ART-naive individuals in African countries (Deuffic-Burban et al., 2007; Jaffar et al., 2004; Morgan et al., 
1997) and a few have directly compared this to estimates derived from high-income countries (Meyer et al.,2007; 
Keller et al., 2009; Lewden et al., 2010; Porter et al., 2000). Fewer still have used data from individuals with 
well-estimated dates of HIV sero-conversion (Anon, 1992; Fauci and Lane, 2005). 
According to UNAIDS (2010) majority of HIV-infected people live in low and middle income countries, 
particularly sub-Saharan Africa but current treatment guidelines are largely based on data from high-income 
countries. Knowledge of effect of ART on CD4 cell count in low income setup would aid in evaluation and 
planning for the response to the HIV epidemic and to inform HIV policy within the government. The information 
is also believed to contribute to the wider body of knowledge on promotion of HIV testing and counseling and to 
form a basis upon which other related studies can be anchored. The study therefore sought to apply paired t-test 
to assess the impact of ART on CD4 cell count among sero-converters in heterosexual relationship in Kisumu 
County, Kenya. 
 
1.1 Objectives of the study 
The objective of this study was to determine the effect of ART on CD4 cell count prior and after initiation of 
antiretroviral therapy among sero-converters in heterosexual relationship in Kisumu Kenya. 
 
1.2 Assumptions of the Study 
ART is a combination of three drugs which varied in some individuals.  We assumed that each different 
combination have equal impact on CD4 cell count although this may not be true.  
2. Literature review 
Sometimes in studying the difference between two means it is possible to use pairs or matched samples 
advantageously. Paired t test is often quite effective in partially eliminating the effects of extraneous factors.  
Matching is commonly used in case-control studies where patients are matched by gender and age  and is often 
used in surgical experiments where two surgical treatments are used on the opposite sides of animals such as rats 
to compare the outcomes (Olive  and  Virgina ,2009).  
 
The t-test requires that observations are drawn from a normally distributed population and the two-sample t-test 
requires that the two populations have the same variance. According to Siegel (1956) traditional parametric tests 
should not be used with extremely small samples, because these tests have several strong assumptions 
underlying their use and that these assumptions cannot be tested when the sample size is small. Campbell et 
al(1995) estimated sample sizes required in two-group comparisons and concluded that N = 5 per group may be 
suitable as long as one accepts very low statistical power. Siegel (1957) stated that there is no alternative to using 
a nonparametric statistical test for samples as small as 6 unless the nature of the population distribution is known 
exactly. A simulated study showed that there is no fundamental objection to using a regular t-test with extremely 
small sample sizes. According to results from simulated study by Winter 2013 assessing the application of t-test 
in extremely small sample sizes, a sample size as small as 2 did not pose problems and Type I error rate did not 
exceed the nominal value of 5% concluding that paired t-test to be feasible with extremely small sample sizes, 
particularly when the within-pair correlation coefficient is high. 
The non parametric alternative to paired t test is wilcoxon test. Wilcoxon test according to Posten (1982) gives 
bigger power compared to t-test for smaller samples while according to Bridge and Sawilowsky (1999) the t-test 
is more powerful than the Wilcoxon test under relatively symmetric distributions. In this test the sum of Type I 
and Type II errors can be minimized according to Mudge et al. (2012) recommendation by adjusting the 
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significance level.   
 
3. Model Development 
3.1 Standard normal (Z- test) 
There are two specific statistical tests used for hypotheses concerning means: the z test and the t test (Bluman, 
2009). The z test is a statistical test for the mean of a population. It can be used when n ≥30, or when the 
population is normally distributed and standard deviation σ is known. Its formula is as shown by (3.1). 
 
                                                                  (3.1) 
 
Where 
 x̅  - The sample mean, 
 μ - Hypothesized population mean 
 σ - Population standard deviation 
 n - The sample size. 
The denominator in (3.1) is the standard error of the mean.  
 
3.2. Student t- test 
 
When the population standard deviation is unknown, the z test is not normally used for testing hypotheses 
involving means. A different test, called the t test, is used. The t distribution was derived by W.S 
Gosset(1876-1937) and published under the pseudonym of ’Student’ and published in 1908 and frequently 
referred to student t distribution (Armitage et al.,2002).The distribution of the variable should be approximately 
normal. The t distribution is similar to the standard normal distribution in that it is bell-shaped, symmetric about 
the mean, the mean, median, and mode are equal to 0 and are located at the center of the distribution and that the 
curve never touches the x axis. The difference with the standard normal distribution is that the variance is greater 
than 1. The t distribution is a family of curves based on the degrees of freedom, which is a number related to 
sample size. As the sample size increases, the t distribution approaches the normal distribution. The formula for t 
test is  
 
                                            (3.2) 
 
The degrees of freedom d.f is n-1 and s is the sample standard deviation. When comparing two means by using 
the t test, the researcher must decide if the two samples are independent or dependent. Independent t test is used 
to test the difference between means when the two samples are independent and when the samples are taken 
from two normally or approximately normally distributed populations. Samples are independent samples when 
they are not related. The t test formula (3.3) is for testing difference in two independent means. 
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                                     (3.3) 
Where the degrees of freedom are equal to the smaller of n1 − 1 and  n1 − 1 
It follows the format of 
                     (3.4) 
Where  x̅1 − x̅2  is the observed difference between sample means and where the expected value μ1-μ2 is 
equal to zero when no difference between population means is hypothesized. The denominator in (3.3) is the 
standard error of the difference between two means.  
Samples are considered to be dependent samples when the subjects are paired or matched in some way. An 
example is where one wants to see whether a drug will affect the reaction time of its users. To test this hypothesis, 
the researcher must pretest the subjects in the sample first and test again after using the drugs. When the samples 
are dependent, a special t test for dependent means is used. This test employs the difference in values of the 
matched pairs (3.5). We first, find the differences of the values of the pairs of data and we will denote it with D 
where 
                                         D =  x̅1 − x̅2                                            (3.5) 
It is assumed that the D has a normal distribution (Ambrosius, 2007). The formula (3.6) shows mean the 
difference where n is the number of data pairs. 
                                                        (3.6) 
The formula (3.7) shows the standard deviation of the differences while (3.8) is the estimated standard error SD 
of the differences. 
                                    (3.7) 
 
                                                          (3.8) 
 
The test value t formula is (3.9) with d.f. n-1. 
                                                         (3.9) 
The expected value μD  is zero if the hypothesis is  μD = 0 . The confidence interval of the difference in the 
paired mean difference is (3.10) 
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                            (3.10) 
The alternative non parametric test for paired t test is Wilcoxon Signed Rank Test. These derived equations are 
based on Ambrosius (2007), Bluman (2009) and petrie and Sabin (2005) 
 
4. Data analysis and results 
4.1 Statistical analysis 
We used paired t test to compare CD4 cell count at most recent visit before ART initiation and at the final CD4 
measurement before exiting the study after using ART. Shapiro-Wilk test was used to test the assumption of 
normal distribution. Study results was interpreted to be significant at P<0.05. Data were analyzed with Stata 12 
(Stata Corporation College Station, Texas, USA). 
 
 
Table1. Baseline Clinical and Socio demographic characteristics of sero-converters in the study 
 
 Progressed to ART initiation? 
Characteristic No(n=24) Yes(n=39) Total(n=63) 
Age Median (IQR) 27.14 (22.24-38.78) 33.21(26.24-47.93) 30.20(25.35-45.44) 
Baseline CD4- Median(IQR) 603 (549-785) 414(351-588) 521(377-644) 
Children with  study partner -Median(IQR) 0 (0-0) 0(0-2) 0(0-1) 
Number  of living children- Median(IQR) 1(0-2) 2(1-5) 2(1-4) 
Income no 17(70.83%) 21(3.85%) 38(60.32%) 
yes 7(29.17%) 18(46.15%) 25(39.68%) 
Sex Female 11(45.83%) 18(46.15%) 29(46.03%) 
Male 13(54.17%) 21(53.85%) 34(53.97%) 
Marital status Cohabiting 0(0%) 3(7.68%) 3(4.76%) 
Married 24(100%) 36(92.31%) 60(95.24%) 
Age category 18-25 years 9(37.50%) 6(15.38%) 15(23.81%) 
25-36 years 8(33.33%) 17(43.59%) 25(39.68%) 
>36 years 7(29.17%) 16(41.03%) 23(36.51%) 
Level of 
education 
primary 14(58.33%) 27(69.23%) 41(65.08%) 
Secondary 8(33.33%) 11(28.21%) 19(30.16%) 
Tertiary 2(8.33%) 1(2.56%) 3(4.76%) 
WHO Staging Stage 1 24(100%) 38(96.15%) 62(98.41%) 
Stage 2 0(0.00%) 1(3.85%) 1(1.59%) 
Baseline CD4 
category 
<500 2(8.70%) 26(68.42%) 28(45.90%) 
501-600 9(39.13%) 3(7.89%) 12(19.67%) 
601-700 2(8.70%) 6(15.79%) 8(13.11%) 
701-800 5(21.74% 2(5.26%) 7(11.48%) 
>800 5(21.74% 1(2.63%) 6(9.84%) 
 
4.2 Results 
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4.2.1 Study participants 
Among 1161 individual who were enrolled as HIV negative partners in sero-discordant hetero-sexual 
relationship, 63(5.4%) got infected with HIV i.e sero-converted and all were followed up. A total 39 (61.9%) out 
of the 63 sero-converters met the eligibility of ART initiation within a median time of 6 months where 7/39 
(17.9 %) were eventually started on ART.   Table 1 shows the demographic characteristics of the 
sero-converters where the baseline median age in years of the cohort was 30.20, IQR (25.35-45.44) (Table1).  A 
total of 34/63 (53.97 %) of the cohort were male; 60/63(95.25%) were married while 15/63(23.8%), 
25/63(39.68%) and 23/63(36.51%) were within the age categories of 18-25, 26-36 and >36 years respectively. 
The median number of children with study partner was 0; IQR (0-1), while the median number of living children 
born to sero-converter was 2; IQR (1-4). A total of 25/63(39.68%) reported earning some monthly income. 
On education, 41/63(65.06), 19/63(30.16%) and 3(4.76%) attained Primary, Secondary and Tertiary levels of 
education respectively. 
The baseline median CD4 cell count/ul was 521 IQR (377-644). The CD4 categories with most individuals of 
28/63(45.90%) was <500 cell/ul; 12/63(19.67%) within (501-600) cells/ul; 8/63(13.11%) within (601-700) 
cells/ul ; 7/63(11.48%)  within (701-800) cells/ul  while  6/63(9.84%)  within  >800 cells/ul category. A 
part from one participant at WHO stage2 of clinical symptoms, the rest 62/63 (98.41%) were at WHO stage 1 at 
the time of sero-conversion( Table 1) 
 
4.2.2. Paired t test results 
Thirty nine individuals (62%) progressed to ART initiation eligibility out of which 7(17.9%) of those were 
eventually initiated on ART. Reasons for not initiating ART were however not documented. We  compared 
measurement of CD4 cell count for the 7 individuals with CD4 cell count measurement taken just before 
initiation of ART and the last CD4 measurement taken before exiting the study having used ART using paired 
t-test method. The median time of using ART for the seven participants was 9 months, IQR (9-30).  
 
Table 2. Paired t test of CD4 cell count before and after initiation of ART 
Variable n Mean Standard Error 
Standard 
Deviation 
95% Confidence 
intervals 
CD4 After 7 683.43 116.98 309.5 397.19 969.67 
CD4 Before 7 442.29 88.96 235.37 224.61 659.97 
Difference 7 241.14 73.94 195.63 60.25 422.07 
 
Table 3 Paired t-test statistical results. 
 
 
The paired t test results (Table2) showed a mean CD4 cell cell/ul before and after initiating ART as 442 and 683 
respectively which give mean difference (D) as 683-442=241 cells/ul. The test statistic (t) =3.26 with degree of 
freedom (d.f).f of n-1 i.e. 7-1=6. Table 3 results test the null hypothesis that there is no impact of ARV on CD4 
cell count among seroconverters i.e P (|T|>|t|) =0. In our case P=0.0172 (Table 3) suggest evidence of difference 
in mean CD4 cell count before and after initiation of ART. We however needed to test the assumption of 
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normality in the paired difference in observation before we could reject the null hypothesis.  
We therefore tested for this assumption by generating a variable which we abbreviated as CD4_Diff by finding 
the difference in CD4 cell count/ul before and after initiation of ART. We then tested this variable for normality 
using Shapiro-Wilk. The paired difference in CD4 cell count did not violate the assumption of normality; W 
0.892, P=0.29329. We therefore reject the null hypothesis and interpreted the results that  in a median time of 9 
months ART treatment resulted in elevation of mean CD4 cell count by a 241 cells/ul;  95% CI (60-422). Each 
observation experienced at least some increase in CD4 cell count after being started on ART. 
 
5. Discussion 
The participants who were initiated on ART were followed up for a median time of 9 months. A significant 
increase in mean CD4 cell count  of 241 cells/ul, 95%CI(60-422), P=0.0172 was evident after using ART for 
the period confirming the effectiveness of ART in reducing the depletion of CD4 cells by HIV hence helping in 
fighting opportunistic infections. The median CD4 cells/ul increase was 235. Few studies on HIV 
sero-discordant heterosexual relationships have assessed the effect of ART on CD4 cell count hence this finding 
are significant as future reference for similar studies. Multiple studies have provided strong support for this 
finding (St Clair et al., 1995; Pagano and Chong, 1995; Hogg et al., 1998; Chiasson et al., 1997) although 
majority of these studies are from middle income countries. A study in India (Dravid et al., 2011) which followed 
patients on ART for 2 years experienced a median rise n CD4 cell count by 220 cells/within 2 years. Although 
the increase in median CD4 cell count was higher in our study and within a shorter follow-up time; the Indian 
study median baseline CD4 was however smaller i.e. 137 cells/ul compared to ours of 346 cells/ul. This suggests 
initiating ART at higher CD4 values would enable quicker recovery in CD4 cell count. A study carried out in a 
Uganda and Kenya cohorts has shown delayed initiation of ART after meeting eligibility (Mujugira et al. 2014) 
hence the benefit of ART may still not be realized. This would therefore call for identifying and addressing 
issues surrounding the delay in initiation of ART. The size of our sample could not allow stratification for 
various groups and hence recommend assessing these groups with bigger samples in future similar studies. 
 
6. Conclusion 
ART is effective in elevating the CD4 cell count among HIV infected individuals initially in sero-discordant 
relationship. There is need to address issues surrounding delays initiation of ART to allow maximum benefit i.e 
quick recovery of CD4 cells which are known to aid in fighting opportunistic infections. 
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